ap5

AP5 is a potent and selective agonist for the GPR40 receptor with positive allosteric modulation of endogenous ligands (AgoPAM). AP5 demonstrates a rat hIP1 EC50 of 0.49 nM against the GPR40 receptor.

D-AP5 (D-APV) is an NMDA receptor antagonist.

DL-AP5 Sodium salt is a NMDA receptor antagonist.

DL-AP5 is the racemic form of a selective N-methyl-D-aspartate (NMDA) receptor antagonist with anticonvulsant effects.

L-AP5 is a NMDA antagonist.

AP5 sodium is a selective, potent, orally active GPR40 receptor agonist that exhibits positive allosteric modulation of endogenous ligands (AgoPAM). sodium exhibits potential for the study of type II diabetes.

DL-AP5 (2-APV) lithium is a competitive antagonist of the NMDA (N-Methyl-D-aspartate) receptor. It exhibits notable analgesic activity and specifically blocks channels in the rabbit retina.

NPEC-caged-D-AP5 is a NMDA receptor antagonist.

AP521 is an agonist of the human 5-HT1A receptor (IC50: 94 nM).

(S)-SNAP5114 is a selective inhibitor of GABA transport, exhibiting IC50 values of 5 μM for hGAT-3 and 21 μM for rGAT-2, and possesses anticonvulsant properties.

PAP508 is a PROTAC specifically targeting AR (Androgen Receptor).

Ap5A (Diadenosine pentaphosphate) is a polyphosphate diadenosine compound that functions as an adenylate kinase inhibitor, with a Ki value of 2.5 nM. This compound is applicable in cancer research.

Ap5dT is an inhibitor of cytosolic thymidine kinase and mitochondrial enzyme, with Ki values of 0.12 μM and 0.50 μM, respectively. This compound is utilized in research related to acute myeloid leukemia.

AP-503 is a selective agonist of GPR133/ADGRD1, with an EC50 of 1.21 nM. It is utilized in research for preventing muscle-related disorders and vestibular dysfunction diseases.

α1A-adrenoceptor antagonist

CAP-53194 is a selective Plk1 inhibitor.

AP-521, a 5-HT1A receptor antagonist, is used potentially for the treatment of anxiety.

ONO 1301 is a prostaglandin I2 mimetic compound with inhibitory activity against thromboxane A2 synthase, and it suppresses pancreatic fibrosis in the DBTC-induced chronic pancreatitis model by inhibiting monocyte activity through both direct effects of ONO 1301 and induction of hepatocyte growth factor. ONO 1301 also promoting HGF synthesis and elevating intracellular cyclic AMP levels via IP-receptor signaling, highlighting its therapeutic relevance in fibrotic disease and inflammation research.

SNAP-5089 is a highly selective alpha1A-adrenoceptor antagonist.

H-Ser-Phe-Leu-Leu-Arg-OH, also known as Coagulation Factor II Receptor (1-5) or Proteinase Activated Receptor 1 (1-5), is utilized in coronary heart disease (CHD) research.

TRAP-5 amide is a peptide agonist for protease-activated receptor 1 (PAR 1) [1].